<![CDATA[SOHO-02 Trial Will Confirm Sevabertinib’s Frontline NSCLC Benefit]]>

Phase 3sevabertinibPositive

AI Analysis

Summary

Xiuning Le discusses the SOHO-02 confirmatory trial required to convert sevabertinib's accelerated approval to full approval for frontline NSCLC treatment.

Clinical Trial Data

Phase

Phase 3

Outcome Details

SOHO-02 confirmatory trial needed to convert accelerated approval to full approval

Importance:5/10

Sentiment:

0.30

oncologyNSCLCaccelerated approvalconfirmatory trialfrontline treatment

Read the original article

Published by Cancer Network on September 24, 2026 6:00 PM

Read Original